Otonomy to Present at Two Upcoming Investor Conferences
Get Alerts OTIC Hot Sheet
Join SI Premium – FREE
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present at two upcoming investor conferences:
- Cowen 40th Annual Health Care Conference in Boston on March 2, 2020 at 12 p.m. ET (9 a.m. PT)
- Oppenheimer 30th Annual Healthcare Conference in New York on March 17, 2020 at 1 p.m. ET (10 a.m. PT)
A live audio webcast of the presentations will be available through the Events page of the company's website (www.otonomy.com).
About Otonomy Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceChloé-Anne RamseyVice President404.865.3601 [email protected]
Investor Inquiries:Westwicke ICRRobert H. UhlManaging Director858.356.5932[email protected]
Source: Otonomy, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
- Japan Maritime Daily to Host International Shipping Seminar in Singapore on October 5, 2026
- SANY Ships Its First Autonomous Mining Trucks to South America
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share